Last reviewed · How we verify

The suppression of graft-versus-host disease in hematopoietic stem cell transplantation — Treatment Landscape & Competitive Intelligence

The suppression of graft-versus-host disease in hematopoietic stem cell transplantation (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating The suppression of graft-versus-host disease in hematopoietic stem cell transplantation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cellcept MYCOPHENOLATE MOFETIL Roche Palo Antimetabolite Immunosuppressant Inosine-5'-monophosphate dehydrogenase 2 1995-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Roche Palo · 1 drug in The suppression of graft-versus-host disease in hematopoietic stem cell transplantation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in The suppression of graft-versus-host disease in hematopoietic stem cell transplantation:

Cite this brief

Drug Landscape (2026). The suppression of graft-versus-host disease in hematopoietic stem cell transplantation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/the-suppression-of-graft-versus-host-disease-in-hematopoietic-stem-cell-transplantation. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing